UNIVERSI
TÄ
TS-
BIBLIOTHEK
P
ADERBORN
Anmelden
Menü
Menü
Start
Hilfe
Blog
Weitere Dienste
Neuerwerbungslisten
Fachsystematik Bücher
Erwerbungsvorschlag
Bestellung aus dem Magazin
Fernleihe
Einstellungen
Sprache
Deutsch
Deutsch
Englisch
Farbschema
Hell
Dunkel
Automatisch
Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist
gegebenenfalls
nur via VPN oder Shibboleth (DFN-AAI) möglich.
mehr Informationen...
Universitätsbibliothek
Katalog
Suche
Details
Zur Ergebnisliste
Ergebnis 12 von 15
Datensatz exportieren als...
BibTeX
Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia
American journal of hematology, 2009-07, Vol.84 (7), p.422-427
Liu, Jiazhuo
Mi, Yingchang
Fu, Mingwei
Yu, Wenjuan
Wang, Ying
Lin, Dong
Bian, Shougeng
Wang, Jianxiang
2009
Volltextzugriff (PDF)
Details
Autor(en) / Beteiligte
Liu, Jiazhuo
Mi, Yingchang
Fu, Mingwei
Yu, Wenjuan
Wang, Ying
Lin, Dong
Bian, Shougeng
Wang, Jianxiang
Titel
Intensive induction chemotherapy with regimen containing intermediate dose cytarabine in the treatment of de novo acute myeloid leukemia
Ist Teil von
American journal of hematology, 2009-07, Vol.84 (7), p.422-427
Ort / Verlag
Hoboken: Wiley Subscription Services, Inc., A Wiley Company
Erscheinungsjahr
2009
Quelle
Wiley Online Library All Journals
Beschreibungen/Notizen
To improve long‐term outcome of de novo acute myeloid leukemia (AML) patients by intermediate dose of cytarabine integrated in induction therapy and to explore the impact of cytogenetic abnormalities on the prognosis. Eighty‐seven AML patients were treated with HAD regimen containing intermediate dose cytarabine (IDAra‐C) as induction therapy, 83 from which with karyotype results were divided into three cytogenetic groups according to SWOG criteria. Complete remission (CR) rate, disease‐free survival (DFS), and overall survival (OS) among different groups were evaluated. The CR rate of the 87 cases was 80/87 (92%). Median DFS and OS have not reached (NR). DFS rates at 1 and 3 years were 76.3% and 63.4%, respectively. OS rates at 1 and 3 years were 86.0% and 58.7%, respectively. According to SWOG criteria, CR rate, median DFS, and OS were 100%, NR and NR for the favorable group; 88.9%, NR, and 16 months for the intermediate group; 83.3%, 4.5 months, and 7.5 months for the adverse group. The differences among the three groups were statistically significant excepting for CR rate between adverse and intermediate groups. HAD regimen containing IDAra‐C as induction chemotherapy regimen is effective in de novo AML of adult patients and can achieve higher CR rate and longer survival than standard dose of cytarabine (SDAra‐C) regimen. Most of the patients were able to endure the therapy. Cytogenetics is still an important prognostic factor despite of the incorporation of IDAra‐C in induction chemotherapy. The differences among the three groups were statistically significant. Am. J. Hematol., 2009. © 2009 Wiley‐Liss, Inc.
Sprache
Englisch
Identifikatoren
ISSN: 0361-8609
eISSN: 1096-8652
DOI: 10.1002/ajh.21441
Titel-ID: cdi_proquest_miscellaneous_20125294
Format
–
Schlagworte
Adolescent
,
Adult
,
Antimetabolites, Antineoplastic - administration & dosage
,
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
,
Biological and medical sciences
,
Chromosome Aberrations
,
Cytarabine - administration & dosage
,
Cytarabine - therapeutic use
,
Daunorubicin - therapeutic use
,
Dose-Response Relationship, Drug
,
Female
,
Harringtonines - therapeutic use
,
Hematologic and hematopoietic diseases
,
Humans
,
Kaplan-Meier Estimate
,
Leukemia, Myeloid, Acute - drug therapy
,
Leukemia, Myeloid, Acute - genetics
,
Leukemia, Myeloid, Acute - physiopathology
,
Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis
,
Male
,
Medical sciences
,
Middle Aged
,
Prognosis
,
Remission Induction
,
Young Adult
Weiterführende Literatur
Empfehlungen zum selben Thema automatisch vorgeschlagen von
bX